Adeona to assess Trimesta drug in female MS patients
The new double-blind, placebo-controlled, randomized Phase II clinical trial is expected to recruit 64 relapsing-remitting or secondary-progressive female MS patients aged between 18 and 50. The primary endpoint
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.